July 31, 2013

The Food and Drug Administration has given Lupin Pharmaceuticals tentative approval to two of its products, the company said Wednesday.

August 10, 2012

Mylan has launched a generic drug used to treat sleep disorders, the company said Friday.

May 15, 2012

Net revenues for Teva rose more than 24% for the first quarter ended March 31, thanks to new drug launches and the company's acquisition of drug maker Cephalon.

April 30, 2012

Mylan plans to start selling a generic version of a drug for sleep disorders starting in June 2016, under a deal with Teva announced Monday.

April 6, 2012

Par Pharmaceutical has started shipping its generic version of a drug for sleep disorders, the company said Friday.

April 5, 2012

Teva is the first company to file for a generic version of a drug to treat sleep disorders, the Food and Drug Administration has determined.

March 30, 2012

Teva Pharmaceutical Industries has launched an authorized generic version of Cephalon's Provigil, used for conditions like shift work sleep disorder and narcolepsy, the company said Friday.

January 23, 2012

The Food and Drug Administration is streamlining the enrollment process for risk evaluation and mitigation strategies for a class of painkillers, the agency said.

January 3, 2012

The Food and Drug Administration is streamlining the enrollment process for risk evaluation and mitigation strategies for a class of painkillers, the agency said Tuesday.

November 21, 2011

Drug maker Impax Labs is looking to challenge the patent protection on a drug used to treat pain related to cancer, the company said Monday.

October 10, 2011

The Federal Trade Commission has given Teva Pharmaceutical Industries the green light to acquire Frazer, Pa.-based drug maker Cephalon, but with some restrictions, Teva said.

August 24, 2011

The final outcome of the battle between Israel’s Teva Pharmaceutical Industries and Canada’s Valeant Pharmaceuticals International to buy Cephalon serves as a good illustration of why it helps to have a plan B.


July 21, 2011

The Food and Drug Administration has approved a risk evaluation and mitigation strategy for two painkillers made by Cephalon, the drug maker said Thursday.

July 15, 2011

Teva Pharmaceutical Industries got the go-ahead from Cephalon’s shareholders to acquire the Frazer, Pa.-based company in a deal worth $6.8 billion.

June 14, 2011

Before they can move ahead with their deal, drug makers Teva and Cephalon must provide the Federal Trade Commission with additional information related to Teva's pending acquisition of Cephalon.

May 16, 2011

Drug maker Mylan has launched a generic treatment for muscle spasms, the company said Friday.

May 2, 2011

Cephalon has another suitor in the form of the world’s largest generic drug company.

April 22, 2011

Valeant Pharmaceuticals International is taking its case directly to Cephalon’s shareholders in its effort to acquire the Frazer, Pa.-based drug maker.

April 13, 2011

Cephalon has lodged a bidder’s statement to acquire Australian drug maker ChemGenex Pharmaceuticals for $167 million, Cephalon said Wednesday.

March 30, 2011

Canadian drug maker Valeant Pharmaceuticals has proposed to buy Cephalon for $5.7 billion, Valeant said Tuesday.

March 25, 2011

A generic painkiller made by Watson Pharmaceuticals infringes a patent covering the branded version, a U.S. District Court ruled.

March 24, 2011

The Consumer Healthcare Products Association may not be painting pink Pepto-Bismol mustaches on a group of Hollywood celebrities and professional athletes as part of the new campaign it plans to fully unveil in June, but the goal is more or less the same as the “Got Milk?” ads.

“Got milk?” has become ubiquitous. There is 100% clarity of message. The milk mustache says it all: Milk is an essential food and an integral part of a healthy diet; it HAS TO BE in your refrigerator, on your breakfast table and in your lunch box.

March 22, 2011

Cephalon plans to acquire a privately owned company developing treatments for cancer, Cephalon said Monday.

March 15, 2011

A generic painkiller made by Watson Pharmaceuticals does not infringe on the patent covering the branded version, a U.S. District Court has ruled.